Telix Pharmaceuticals Limited (TLX)

Telix Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	207.16	439.6	84.01	79.07	16.02	60.13
Cash & Short-Term Investments	207.16	439.6	84.01	79.07	16.02	60.13
Cash Growth	161.27%	423.29%	6.25%	393.44%	-73.35%	91.92%
Accounts Receivable	123.63	86.3	44.16	26.75	0.53	0.12
Other Receivables	-	6.21	4.84	4.46	14.63	10.82
Receivables	123.63	92.51	49	31.21	15.16	10.95
Inventory	35.23	23.61	11.8	5.76	2.51	0.49
Prepaid Expenses	-	6.86	8.47	1.7	0.88	0.66
Other Current Assets	32	5.89	5.22	-	-	-
Total Current Assets	398.01	568.45	158.49	117.74	34.57	72.23
Property, Plant & Equipment	74.18	33.62	20.79	12.8	4.6	3.72
Long-Term Investments	4.06	3.77	8.36	-	-	-
Goodwill	185.81	66	3.3	3.75	2.98	3.26
Other Intangible Assets	398.36	191.53	71.45	36.34	37.54	42.4
Long-Term Deferred Tax Assets	75.77	28.92	13.94	2.7	-	-
Other Long-Term Assets	53.76	46.16	0.4	0.22	0.15	0.14
Total Assets	1,190	938.44	276.73	173.56	79.85	121.76
Accounts Payable	51.69	42.51	22.38	11.42	8.64	4.48
Accrued Expenses	59.09	47.89	38.2	25.23	8.48	1.92
Short-Term Debt	-	-	-	-	0.01	-
Current Portion of Long-Term Debt	12.69	11.75	0.66	-	-	0.2
Current Portion of Leases	8.37	1.54	0.41	0.44	0.45	0.39
Current Income Taxes Payable	51.74	30.06	13.06	4.98	-	-
Current Unearned Revenue	5.3	7.54	7.89	3.63	4.51	2.55
Other Current Liabilities	109.71	63.49	29.92	12.46	5.53	5.85
Total Current Liabilities	298.58	204.78	112.52	58.15	27.62	15.4
Long-Term Debt	371.48	341.49	5.6	2.25	-	0.07
Long-Term Leases	25.71	5.04	5.23	4.41	1.39	1.04
Long-Term Unearned Revenue	1.02	3.32	9.71	16.77	17.84	21.99
Pension & Post-Retirement Benefits	0.36	0.31	0.22	0.15	0.1	-
Long-Term Deferred Tax Liabilities	39.19	5.81	-	-	-	-
Other Long-Term Liabilities	31.68	26.06	41.93	37.45	31.33	22.31
Total Liabilities	768.01	586.8	175.22	119.18	78.28	60.8
Common Stock	473.11	369.31	304.2	252.14	124.22	128.88
Retained Earnings	-150.98	-131.79	-179.73	-185.42	-126.13	-71.72
Comprehensive Income & Other	99.81	114.12	-22.97	-12.34	3.48	3.79
Shareholders' Equity	421.94	351.64	101.51	54.38	1.57	60.96
Total Liabilities & Equity	1,190	938.44	276.73	173.56	79.85	121.76
Total Debt	418.25	359.83	11.89	7.1	1.85	1.7
Net Cash (Debt)	-211.1	79.77	72.11	71.97	14.18	58.43
Net Cash Growth	-	10.61%	0.21%	407.61%	-75.74%	95.85%
Net Cash Per Share	-0.81	0.23	0.22	0.23	0.05	0.23
Filing Date Shares Outstanding	338.4	329.55	323.96	316.71	308.2	280.41
Total Common Shares Outstanding	338.4	334.73	323.73	316.34	285.07	280.41
Working Capital	99.43	363.67	45.97	59.59	6.95	56.84
Book Value Per Share	1.25	1.05	0.31	0.17	0.01	0.22
Tangible Book Value	-162.23	94.11	26.75	14.29	-38.95	15.3
Tangible Book Value Per Share	-0.48	0.28	0.08	0.05	-0.14	0.05
Land	18.53	16.24	14.15	6.68	1.71	1.9
Machinery	20.96	11.49	1.7	1.16	1.34	0.49
Leasehold Improvements	3.35	2.02	1.3	1.05	0.27	0.18

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q